Cart
sales@molnova.com
GSK4112
CAS No. 1216744-19-2
GSK4112( SR6452 | GSK-4112 | GSK 4112 | SR-6452 | SR 6452 )
Catalog No. M10812 CAS No. 1216744-19-2
A potent and selective small molecule Rev-erbα agonist with EC50 of 0.4 uM in biochemical assay.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 39 | In Stock |
|
| 10MG | 69 | In Stock |
|
| 25MG | 147 | In Stock |
|
| 50MG | 266 | In Stock |
|
| 100MG | 478 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameGSK4112
-
NoteResearch use only, not for human use.
-
Brief DescriptionA potent and selective small molecule Rev-erbα agonist with EC50 of 0.4 uM in biochemical assay.
-
DescriptionA potent and selective small molecule Rev-erbα agonist with EC50 of 0.4 uM in biochemical assay; mediates the repression of Rev-erbα target gene bmal1 in liver cells, and inhibits and shifts the phase of gluconeogenesis in primary mouse hepatocytes.
-
In VitroGSK4112 (0-100 μM; 1 h) interacts with Rev-erbα with an EC50 value of 0.4 μM.GSK4112 (10 μM; 6 h) represses expression of bmal1 and the target genes associated with the pathway of gluconeogenesis, recruits HDAC3 and modulates the effect of Rev-erbα on oscillation of hepatic gene expression.GSK4112 (10 μM; 16 h) reduces glucose output in murine hepatocytes. RT-PCR Cell Line:HepG2 cell line Concentration:10 μM Incubation Time:6 hours Result:Repressed mRNA levels of bmal1, G6 Pase, PEPCK and PGC1α.
-
In VivoGSK4112 (25 mg/kg; i.p. 0.5 h before Jo2 exposure) attenuates Fas-induced hepatic damage. Animal Model:Male C57BL/6 mice with Fas-induced acute hepatic damage Dosage:25 mg/kg Administration:Intraperitoneal injection; 25 mg/kg; 0.5 h before Jo2 exposure Result:Obviously ameliorated the degree of liver damage, suppressed Jo2-induced ALT and AST increasing, improved the survival rate of mice and suppressed Fas-induced hepatocyte apoptosis.
-
SynonymsSR6452 | GSK-4112 | GSK 4112 | SR-6452 | SR 6452
-
PathwayAutophagy
-
TargetAutophagy
-
RecptorRev-ErbBα
-
Research AreaMetabolic Disease
-
Indication——
Chemical Information
-
CAS Number1216744-19-2
-
Formula Weight396.8883
-
Molecular FormulaC18H21ClN2O4S
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESO=C(OC(C)(C)C)CN(CC1=CC=C(Cl)C=C1)CC2=CC=C([N+]([O-])=O)S2
-
Chemical NameGlycine, N-[(4-chlorophenyl)methyl]-N-[(5-nitro-2-thienyl)methyl]-, 1,1-dimethylethyl ester
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Grant D, et al. ACS Chem Biol. 2010 Oct 15;5(10):925-32.
2. Trump RP, et al. J Med Chem. 2013 Jun 13;56(11):4729-37.
3. Chandra V, et al. Autophagy. 2015 Nov 2;11(11):1987-1997.
molnova catalog
related products
-
LYN-1604 2HCl 221675...
LYN-1604 is a novel ULK1 activator.It inducing cell death involved in ATF3, RAD21, and caspase3, accompanied by autophagy and apoptosis.?LYN-1604, to be the best candidate for a ULK1 agonist.?LYN-1604 induced cell death involved in ATF3, RAD21, and caspase3, accompanied by autophagy and apoptosis.?LYN-1604 has potential for good therapeutic effects on TNBC by targeting ULK1-modulated cell death in vivo.
-
BRD5631
A small-molecule enhancer of autophagy through an mTOR-independent pathway; significantly reduces the number of eGFP-HDQ74-positive cells, and increases the transcript level of p62 in Atg5+/+ MEFs.
-
A-867744
A-867744 is an effective and selective type II positive allosteric modulator of the α7 nAChR (EC50: 1.0 μM).
